Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.32 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | F2R | P25116 | 1/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248088 | 0.91 | TSHR (0.39) | SMN1; SMN2TSHRMAPTLMNACYP1A2 | |
| SCHEMBL3829548 | 0.91 | TSHR (0.39) | SMN1; SMN2TSHRMAPTLMNACYP1A2 | |
| SCHEMBL9446411 | 0.91 | TSHR (0.39) | SMN1; SMN2TSHRMAPTLMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL21805904 | 0.89 | TSHR (0.38) | SMN1; SMN2TSHRMAPTLMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL16010588 | 0.89 | TSHR (0.38) | SMN1; SMN2TSHRMAPTLMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL4246521 | 0.89 | TSHR (0.38) | SMN1; SMN2TSHRMAPTLMNACYP1A2 | |
| SCHEMBL19049370 | 0.81 | ITGB3 (0.38) | SMN1; SMN2TSHRLMNAHRH3CYP1A2 | |
| SCHEMBL25212730 | 0.79 | GAA (0.38) | SMN1; SMN2TSHRMAPTLMNAGAA | |
| SCHEMBL357615 | 0.75 | CYP1A2 (0.43) | SMN1; SMN2TSHRMAPTLMNACYP1A2 | |
| SCHEMBL799032 | 0.75 | CYP1A2 (0.43) | SMN1; SMN2TSHRMAPTLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3342770-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | AstraZeneca AB (SE) | 2018-07-04 | — | — | EP | claimed |
| US-20180016259-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2018-01-18 | — | — | US | claimed |
| EP-2964638-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | Astrazeneca AB (SE) | 2016-01-13 | — | — | EP | claimed |
| WO-2014135876-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2014-09-12 | — | — | WO | claimed |
| US-20140255428-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | ASTRAZENECA AB (SE) | 2014-09-11 | — | — | US | claimed |
| EP-3342770-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | AstraZeneca AB (SE) | 2018-07-04 | — | — | EP | disclosed |
| US-20180016259-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2018-01-18 | — | — | US | disclosed |
| EP-2964638-B1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2017-08-09 | — | — | EP | disclosed |
| EP-2964638-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | Astrazeneca AB (SE) | 2016-01-13 | — | — | EP | disclosed |
| US-9066979-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| WO-2014135876-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2014-09-12 | — | — | WO | disclosed |
| US-20140255428-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | ASTRAZENECA AB (SE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016259-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | EGFR, ERBB2, ABL1 | SMN1; SMN2 4762/4885ACE 657/4885TSHR 2224/4885 |
| US-20140255428-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | EGFR, ERBB2, ABL1 | SMN1; SMN2 4816/4885ACE 584/4885TSHR 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.